In-depth analysis of drug resistance to apelvis and its influencing factors

Alpelisib (Alpelisib), as an important targeted drug in the treatment of metastatic breast cancer, has brought new hope to many patients. However, like many drugs, Apelvis also faces the challenge of drug resistance. Drug resistance refers to the phenomenon that the therapeutic effect of a drug gradually weakens or even disappears completely during continued use. This is usually caused by the adaptive changes of tumor cells to the drug.

For apelvis, the emergence of resistance is a complex and multifactorial process. Research shows that genetic mutations in breast cancer cells, reactivation of signaling pathways, and a series of complex molecular mechanisms may lead to patients' reduced sensitivity to apelvis. In addition, prolonged drug exposure may also induce adaptive changes in tumor cells, thereby reducing the efficacy of apelix.

It is important to note that not all patients treated with apelvis will develop drug resistance. In fact, for many patients, Apelvis can still exert significant anti-tumor effects and effectively prolong patient survival. Especially for postmenopausal female or male patients, if they are diagnosed with advanced hormone receptor-positive, HER2-negative breast cancer and develop PIK3CA mutations after hormone therapy, the treatment regimen of apelvis combined with fulvestrant may bring them longer progression-free survival and overall survival.

Although early results from the SOLAR-1 trial showed that the combination of apelvis and fulvestrant improved overall survival by 8 months compared with fulvestrant alone, this result has not yet reached statistical significance. However, this does not affect the important role of apelix in the treatment of this type of breast cancer patients. At the same time, doctors should also adjust treatment plans according to the specific conditions of patients to maximize treatment effects and reduce the occurrence of drug resistance.